Report of the Key Opinion Leaders Meeting on Stem Cell-derived Beta Cells

Jon Odorico; James Markmann; Douglas Melton; Julia Greenstein; Albert Hwa; Cristina Nostro; Alireza Rezania; Jose Oberholzer; Daniel Pipeleers; Luhan Yang; Chad Cowan; Danwei Huangfu; Dieter Egli; Uri Ben-David; Ludovic Vallier; Shane T. Grey; Qizhi Tang; Bart Roep; Camilo Ricordi; Ali Naji; Giuseppe Orlando; Daniel G. Anderson; Mark Poznansky; Barbara Ludwig; Alice Tomei; Dale L. Greiner; Melanie Graham; Melissa Carpenter; Giovanni Migliaccio; Kevin D'Amour; Bernhard Hering; Lorenzo Piemonti; Thierry Berney; Mike Rickels; Thomas Kay; Ann Adams

doi:10.1097/TP.0000000000002217

Report of the Key Opinion Leaders Meeting on Stem Cell-derived Beta Cells

Jon Odorico, James Markmann, Douglas Melton, Julia Greenstein, Albert Hwa, Cristina Nostro, Alireza Rezania, Jose Oberholzer, Daniel Pipeleers, Luhan Yang, Chad Cowan, Danwei Huangfu, Dieter Egli, Uri Ben-David, Ludovic Vallier, Shane T. Grey, Qizhi Tang, Bart Roep, Camilo Ricordi, Ali NajiGiuseppe Orlando, Daniel G. Anderson, Mark Poznansky, Barbara Ludwig, Alice Tomei, Dale L. Greiner, Melanie Graham, Melissa Carpenter, Giovanni Migliaccio, Kevin D'Amour, Bernhard Hering, Lorenzo Piemonti, Thierry Berney, Mike Rickels, Thomas Kay, Ann Adams

Research output: Contribution to journal › Review article › peer-review

Abstract

Beta cell replacement has the potential to restore euglycemia in patients with insulin-dependent diabetes. Although great progress has been made in establishing allogeneic islet transplantation from deceased donors as the standard of care for those with the most labile diabetes, it is also clear that the deceased donor organ supply cannot possibly treat all those who could benefit from restoration of a normal beta cell mass, especially if immunosuppression were not required. Against this background, the International Pancreas and Islet Transplant Association in collaboration with the Harvard Stem Cell Institute, the Juvenile Diabetes Research Foundation (JDRF), and the Helmsley Foundation held a 2-day Key Opinion Leaders Meeting in Boston in 2016 to bring together experts in generating and transplanting beta cells derived from stem cells. The following summary highlights current technology, recent significant breakthroughs, unmet needs and roadblocks to stem cell-derived beta cell therapies, with the aim of spurring future preclinical collaborative investigations and progress toward the clinical application of stem cell-derived beta cells.

Original language	English
Pages (from-to)	1223-1229
Number of pages	7
Journal	Transplantation
Volume	102
Issue number	8
DOIs	https://doi.org/10.1097/TP.0000000000002217
State	Published - 1 Aug 2018
Externally published	Yes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

All Science Journal Classification (ASJC) codes

Transplantation

Access to Document

10.1097/TP.0000000000002217

Cite this

Odorico, J., Markmann, J., Melton, D., Greenstein, J., Hwa, A., Nostro, C., Rezania, A., Oberholzer, J., Pipeleers, D., Yang, L., Cowan, C., Huangfu, D., Egli, D., Ben-David, U., Vallier, L., Grey, S. T., Tang, Q., Roep, B., Ricordi, C., ... Adams, A. (2018). Report of the Key Opinion Leaders Meeting on Stem Cell-derived Beta Cells. Transplantation, 102(8), 1223-1229. https://doi.org/10.1097/TP.0000000000002217

@article{ca47586a8550401884ce78144e092532,

title = "Report of the Key Opinion Leaders Meeting on Stem Cell-derived Beta Cells",

abstract = "Beta cell replacement has the potential to restore euglycemia in patients with insulin-dependent diabetes. Although great progress has been made in establishing allogeneic islet transplantation from deceased donors as the standard of care for those with the most labile diabetes, it is also clear that the deceased donor organ supply cannot possibly treat all those who could benefit from restoration of a normal beta cell mass, especially if immunosuppression were not required. Against this background, the International Pancreas and Islet Transplant Association in collaboration with the Harvard Stem Cell Institute, the Juvenile Diabetes Research Foundation (JDRF), and the Helmsley Foundation held a 2-day Key Opinion Leaders Meeting in Boston in 2016 to bring together experts in generating and transplanting beta cells derived from stem cells. The following summary highlights current technology, recent significant breakthroughs, unmet needs and roadblocks to stem cell-derived beta cell therapies, with the aim of spurring future preclinical collaborative investigations and progress toward the clinical application of stem cell-derived beta cells.",

author = "Jon Odorico and James Markmann and Douglas Melton and Julia Greenstein and Albert Hwa and Cristina Nostro and Alireza Rezania and Jose Oberholzer and Daniel Pipeleers and Luhan Yang and Chad Cowan and Danwei Huangfu and Dieter Egli and Uri Ben-David and Ludovic Vallier and Grey, \{Shane T.\} and Qizhi Tang and Bart Roep and Camilo Ricordi and Ali Naji and Giuseppe Orlando and Anderson, \{Daniel G.\} and Mark Poznansky and Barbara Ludwig and Alice Tomei and Greiner, \{Dale L.\} and Melanie Graham and Melissa Carpenter and Giovanni Migliaccio and Kevin D'Amour and Bernhard Hering and Lorenzo Piemonti and Thierry Berney and Mike Rickels and Thomas Kay and Ann Adams",

year = "2018",

month = aug,

day = "1",

doi = "10.1097/TP.0000000000002217",

language = "الإنجليزيّة",

volume = "102",

pages = "1223--1229",

journal = "Transplantation",

issn = "0041-1337",

publisher = "Lippincott Williams and Wilkins",

number = "8",

}

Odorico, J, Markmann, J, Melton, D, Greenstein, J, Hwa, A, Nostro, C, Rezania, A, Oberholzer, J, Pipeleers, D, Yang, L, Cowan, C, Huangfu, D, Egli, D, Ben-David, U, Vallier, L, Grey, ST, Tang, Q, Roep, B, Ricordi, C, Naji, A, Orlando, G, Anderson, DG, Poznansky, M, Ludwig, B, Tomei, A, Greiner, DL, Graham, M, Carpenter, M, Migliaccio, G, D'Amour, K, Hering, B, Piemonti, L, Berney, T, Rickels, M, Kay, T & Adams, A 2018, 'Report of the Key Opinion Leaders Meeting on Stem Cell-derived Beta Cells', Transplantation, vol. 102, no. 8, pp. 1223-1229. https://doi.org/10.1097/TP.0000000000002217

TY - JOUR

T1 - Report of the Key Opinion Leaders Meeting on Stem Cell-derived Beta Cells

AU - Odorico, Jon

AU - Markmann, James

AU - Melton, Douglas

AU - Greenstein, Julia

AU - Hwa, Albert

AU - Nostro, Cristina

AU - Rezania, Alireza

AU - Oberholzer, Jose

AU - Pipeleers, Daniel

AU - Yang, Luhan

AU - Cowan, Chad

AU - Huangfu, Danwei

AU - Egli, Dieter

AU - Ben-David, Uri

AU - Vallier, Ludovic

AU - Grey, Shane T.

AU - Tang, Qizhi

AU - Roep, Bart

AU - Ricordi, Camilo

AU - Naji, Ali

AU - Orlando, Giuseppe

AU - Anderson, Daniel G.

AU - Poznansky, Mark

AU - Ludwig, Barbara

AU - Tomei, Alice

AU - Greiner, Dale L.

AU - Graham, Melanie

AU - Carpenter, Melissa

AU - Migliaccio, Giovanni

AU - D'Amour, Kevin

AU - Hering, Bernhard

AU - Piemonti, Lorenzo

AU - Berney, Thierry

AU - Rickels, Mike

AU - Kay, Thomas

AU - Adams, Ann

PY - 2018/8/1

Y1 - 2018/8/1

N2 - Beta cell replacement has the potential to restore euglycemia in patients with insulin-dependent diabetes. Although great progress has been made in establishing allogeneic islet transplantation from deceased donors as the standard of care for those with the most labile diabetes, it is also clear that the deceased donor organ supply cannot possibly treat all those who could benefit from restoration of a normal beta cell mass, especially if immunosuppression were not required. Against this background, the International Pancreas and Islet Transplant Association in collaboration with the Harvard Stem Cell Institute, the Juvenile Diabetes Research Foundation (JDRF), and the Helmsley Foundation held a 2-day Key Opinion Leaders Meeting in Boston in 2016 to bring together experts in generating and transplanting beta cells derived from stem cells. The following summary highlights current technology, recent significant breakthroughs, unmet needs and roadblocks to stem cell-derived beta cell therapies, with the aim of spurring future preclinical collaborative investigations and progress toward the clinical application of stem cell-derived beta cells.

AB - Beta cell replacement has the potential to restore euglycemia in patients with insulin-dependent diabetes. Although great progress has been made in establishing allogeneic islet transplantation from deceased donors as the standard of care for those with the most labile diabetes, it is also clear that the deceased donor organ supply cannot possibly treat all those who could benefit from restoration of a normal beta cell mass, especially if immunosuppression were not required. Against this background, the International Pancreas and Islet Transplant Association in collaboration with the Harvard Stem Cell Institute, the Juvenile Diabetes Research Foundation (JDRF), and the Helmsley Foundation held a 2-day Key Opinion Leaders Meeting in Boston in 2016 to bring together experts in generating and transplanting beta cells derived from stem cells. The following summary highlights current technology, recent significant breakthroughs, unmet needs and roadblocks to stem cell-derived beta cell therapies, with the aim of spurring future preclinical collaborative investigations and progress toward the clinical application of stem cell-derived beta cells.

UR - http://www.scopus.com/inward/record.url?scp=85050670486&partnerID=8YFLogxK

U2 - 10.1097/TP.0000000000002217

DO - 10.1097/TP.0000000000002217

M3 - مقالة مرجعية

SN - 0041-1337

VL - 102

SP - 1223

EP - 1229

JO - Transplantation

JF - Transplantation

IS - 8

ER -

Report of the Key Opinion Leaders Meeting on Stem Cell-derived Beta Cells

Abstract

UN SDGs

All Science Journal Classification (ASJC) codes

Access to Document

Other files and links

Fingerprint

Cite this